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Background: Tigecycline, a member of a new class of
antimicrobials (glycylcyclines), has been shown to have
potent broad spectrum activity against most commonly
encountered species responsible for hospital acquired infec-
tions. Cross-resistance to several classes of antimicrobials
is often seen in nosocomial pathogens. The T.E.S.T. pro-
gram determined the in vitro activity of tigecycline against
strains of Enterobacteriaceae cross-resistant to one or
more of the following antimicrobials: amoxicillin-clavulanic
acid, piperacillin-tazobactam, levoﬂoxacin, ceftriaxone,
cefepime, ampicillin, amikacin, minocycline, ceftazidime
and imipenem. The isolates were collected from 335 inves-
tigational sties in 47 countries throughout 2004—2007.
Methods: A total of 26,791 clinical Enterobacteriaceae
were identiﬁed to the species level at each site and
conﬁrmed by the central laboratory. Minimum Inhibitory
Concentrations (MICs) were determined by the local lab-
oratory using broth microdilution panels. Antimicrobial
resistance was interpreted according to CLSI breakpoints
with TIG susceptible and resistant breakpoints deﬁned
as = 8mcg/ml, respectively.
Results: 1,387/16,289 (8.5%) E. coli and Klebsiella spp
were ESBL producers. Of the Enterobacteriaceae presented,
13% were resistance to levoﬂoxacin, 8% to minocycline,
1.1% to amikacin, 0.2% to imipenem, and 0.8% to tigecy-
cline. Of the 10,348 Enterobacter spp. and S. marcescens
collected, 593 (5.7%) presented resistance to ceftriaxone
and ceftazidime but susceptible to cefepime suggestive of
AmpC phenotype. Only 877 (3.3%) of the Enterobacteriaceae
showed any degree of non-susceptibility against tigecycline
with MICs ranging from 4 to 8mcg/mL. Tigecycline also
showed excellent inhibitory activity against members of
Enterobacteriaceae that were resistant to amikacin, lev-
oﬂoxacin, minocycline and imipenem inhibiting 94%, 92%,
72% and 91% of isolates respectively.
Conclusions: The presented data suggest that tigecycline
is little affected by this cross-resistance phenomenon and
may be an effective and reliable therapeutic option against
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This study describes the pattern and extent of drug resis-
tance in 1774 strains of Salmonella enterica serovar Typhi (S.
Typhi) isolated across Asia between 1993 and 2005 and char-
acterizes the molecular mechanisms underlying the reduced
susceptibility to the ﬂuoroquinolones in these strains. In
1393 S. Typhi collected in southern Vietnam, the propor-
tion of MDR has remained at high levels since 1993 (50% in
2004) and there was a dramatic increase in nalidixic acid
resistance between 1993 (4%) and 2005 (97%). In a cross-
sectional sample of 381 S. Typhi from 8 Asian countries,
Bangladesh, China, India, Indonesia, Laos, Nepal, Pakistan
and central Vietnam collected in 2002 to 2004, variable
rates of multidrug resistance (16—37%) and nalidixic acid
resistance (5—51%) were found. The eight Asian countries
involved in this study are home to approximately 80% of
the world’s typhoid fever cases. These results document the
scale of drug resistance across Asia.
The Ser83♦Phe substitution in GyrA was the predomi-
nant alteration in S. Typhifrom Vietnam (117/127 isolates,
92.1%). No mutations in gyrB, parC and parE were detected
in 55 of these strains. In vitro time-kill experiments showed
a reduction in the efﬁcacy of oﬂoxacin against strains har-
bouring a single amino acid substitution at codon 83 or 87
of GyrA, this effect was more marked against a strain with
a double substitution. The 8-methoxy ﬂuoroquinolone gati-
ﬂoxacin showed rapid killing of S. Typhi harbouring both the
single and double amino acid substitutions.
doi:10.1016/j.ijid.2008.05.299
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Background: The intrinsic resistance of Pseudomonas
aeruginosa towards several antimicrobial agents has con-
tributed to its role as an effective opportunistic pathogen
and its emergence as one of the most problematic human
pathogens. The aim of this study was to assess the suscepti-
bility patterns of eight commonly used antimicrobial agents
against clinical isolates of Pseudomonas aeruginosa.
